588 related articles for article (PubMed ID: 33649166)
21. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
22. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
Ichiki Y; Takenoyama M; Mizukami M; So T; Sugaya M; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
J Immunol; 2004 Apr; 172(8):4844-50. PubMed ID: 15067062
[TBL] [Abstract][Full Text] [Related]
25. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
26. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
27. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
[TBL] [Abstract][Full Text] [Related]
28. Identification of peptide-specific TCR genes by in vitro peptide stimulation and CDR3 length polymorphism analysis.
Shao H; Lin Y; Wang T; Ou Y; Shen H; Tao C; Wu F; Zhang W; Bo H; Wang H; Huang S
Cancer Lett; 2015 Jul; 363(1):83-91. PubMed ID: 25890221
[TBL] [Abstract][Full Text] [Related]
29. Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Li D; Bentley C; Anderson A; Wiblin S; Cleary KLS; Koustoulidou S; Hassanali T; Yates J; Greig J; Nordkamp MO; Trenevska I; Ternette N; Kessler BM; Cornelissen B; Cragg MS; Banham AH
Cancer Res; 2017 May; 77(10):2699-2711. PubMed ID: 28363997
[TBL] [Abstract][Full Text] [Related]
30. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
[TBL] [Abstract][Full Text] [Related]
31. T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.
Klebanoff CA
Cancer Immunol Res; 2022 Aug; 10(8):919. PubMed ID: 35767244
[TBL] [Abstract][Full Text] [Related]
32. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
34. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.
Couch ME; Ferris RL; Brennan JA; Koch WM; Jaffee EM; Leibowitz MS; Nepom GT; Erlich HA; Sidransky D
Clin Cancer Res; 2007 Dec; 13(23):7199-206. PubMed ID: 18056201
[TBL] [Abstract][Full Text] [Related]
35. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
Panchal A; Seto P; Wall R; Hillier BJ; Zhu Y; Krakow J; Datt A; Pongo E; Bagheri A; Chen TT; Degenhardt JD; Culp PA; Dettling DE; Vinogradova MV; May C; DuBridge RB
MAbs; 2020; 12(1):1792130. PubMed ID: 32684124
[TBL] [Abstract][Full Text] [Related]
36. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Ferrini S; Sforzini S; Canevari S
Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
[No Abstract] [Full Text] [Related]
37. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
Groth A; Salnikov AV; Ottinger S; Gladkich J; Liu L; Kallifatidis G; Salnikova O; Ryschich E; Giese N; Giese T; Momburg F; Büchler MW; Moldenhauer G; Herr I
Clin Cancer Res; 2012 Feb; 18(4):1028-38. PubMed ID: 22228630
[TBL] [Abstract][Full Text] [Related]
38. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
39. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
40. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
